Profile data is unavailable for this security.
About the company
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
- Revenue in USD (TTM)2.69bn
- Net income in USD-214.04m
- Incorporated1995
- Employees6.50k
- LocationExact Sciences Corp5505 Endeavor LaneMADISON 53719United StatesUSA
- Phone+1 (608) 284-5700
- Fax+1 (608) 284-5701
- Websitehttps://www.exactsciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nuvalent Inc | 0.00 | -224.29m | 6.75bn | 127.00 | -- | 6.05 | -- | -- | -3.48 | -3.48 | 0.00 | 15.81 | 0.00 | -- | -- | 0.00 | -27.79 | -- | -29.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
Legend Biotech Corp (ADR) | 520.18m | -348.13m | 7.51bn | 2.40k | -- | 7.02 | -- | 14.44 | -1.91 | -1.91 | 2.85 | 6.08 | 0.291 | 9.29 | 1,434.99 | 288,990.60 | -19.47 | -37.71 | -22.25 | -47.19 | 62.88 | -- | -66.92 | -286.51 | 4.90 | -- | 0.237 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
Madrigal Pharmaceuticals Inc | 76.81m | -518.67m | 7.58bn | 376.00 | -- | 9.69 | -- | 98.66 | -25.07 | -25.07 | 3.71 | 35.64 | 0.1172 | -- | -- | 204,289.90 | -79.11 | -62.09 | -100.35 | -74.81 | 96.37 | -- | -675.24 | -- | 5.93 | -- | 0.1309 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
Tempus AI Inc | 640.44m | -800.71m | 9.23bn | 2.30k | -- | 184.70 | -- | 14.41 | -8.29 | -8.29 | 4.44 | 0.3459 | -- | -- | -- | -- | -- | -- | -- | -- | 53.18 | -- | -116.06 | -- | 2.55 | -14.95 | 0.891 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
Revolution Medicines Inc | 742.00k | -567.06m | 9.55bn | 490.00 | -- | 6.16 | -- | 12,865.84 | -3.59 | -3.59 | 0.0047 | 9.34 | 0.0005 | -- | 4.80 | 1,962.96 | -41.28 | -29.76 | -44.46 | -32.59 | -- | -- | -76,423.31 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
Exact Sciences Corp | 2.69bn | -214.04m | 9.79bn | 6.50k | -- | 3.18 | 5,371.58 | 3.64 | -1.17 | -1.17 | 14.70 | 17.35 | 0.4089 | 5.40 | 11.60 | 414,204.30 | -3.25 | -9.71 | -3.58 | -10.60 | 72.96 | 74.10 | -7.95 | -28.21 | 1.93 | -- | 0.4459 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
Charles River Lbrtrs ntrntl Inc | 4.06bn | 413.08m | 10.01bn | 20.00k | 25.13 | 2.72 | 13.03 | 2.47 | 8.01 | 8.01 | 78.63 | 73.97 | 0.5203 | 8.27 | 5.23 | 203,045.80 | 5.48 | 6.46 | 6.33 | 7.62 | 35.93 | 36.99 | 10.54 | 11.58 | 1.14 | 4.96 | 0.3784 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Exelixis Inc | 2.08bn | 466.92m | 10.17bn | 1.31k | 23.18 | 4.57 | 20.56 | 4.89 | 1.57 | 1.57 | 6.92 | 7.96 | 0.7012 | 3.39 | 8.04 | 1,589,006.00 | 15.73 | 8.86 | 18.08 | 9.91 | 96.25 | 96.30 | 22.43 | 15.43 | 3.88 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
Medpace Holdings Inc | 2.07bn | 365.57m | 10.50bn | 5.90k | 29.58 | 11.89 | 26.62 | 5.07 | 11.42 | 11.42 | 64.70 | 28.42 | 1.16 | -- | 6.85 | 350,994.30 | 20.48 | 13.94 | 43.51 | 23.18 | 29.69 | 28.84 | 17.66 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
Sarepta Therapeutics Inc | 1.64bn | 121.85m | 10.91bn | 1.31k | 94.28 | 8.97 | 67.99 | 6.65 | 1.22 | 1.22 | 16.30 | 12.79 | 0.489 | 0.5703 | 4.35 | 1,248,362.00 | 3.63 | -21.63 | 4.38 | -25.75 | 85.92 | 86.65 | 7.43 | -77.05 | 3.03 | -- | 0.5013 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
Vaxcyte Inc | 0.00 | -507.65m | 11.04bn | 254.00 | -- | 3.34 | -- | -- | -4.55 | -4.55 | 0.00 | 27.47 | 0.00 | -- | -- | 0.00 | -20.08 | -34.22 | -20.95 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
BIO-TECHNE Corp | 1.17bn | 150.68m | 11.33bn | 3.10k | 79.13 | 5.53 | 43.22 | 9.67 | 0.9402 | 0.9402 | 7.29 | 13.46 | 0.4267 | 2.15 | 5.47 | 377,930.00 | 5.49 | 9.42 | 5.77 | 10.04 | 65.93 | 67.29 | 12.86 | 21.41 | 3.26 | 18.07 | 0.123 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
Neurocrine Biosciences, Inc. | 2.24bn | 385.90m | 12.72bn | 1.70k | 34.04 | 4.73 | 30.91 | 5.67 | 3.73 | 3.73 | 21.67 | 26.87 | 0.7027 | 0.8901 | 4.99 | 1,602,000.00 | 12.09 | 9.77 | 14.67 | 12.19 | 98.52 | 98.51 | 17.21 | 14.79 | 4.26 | 10.28 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Insmed Inc | 342.96m | -864.29m | 13.09bn | 912.00 | -- | 27.41 | -- | 38.16 | -5.56 | -5.56 | 2.21 | 2.70 | 0.2031 | 0.8848 | 8.81 | 376,050.40 | -51.17 | -40.96 | -59.16 | -46.88 | 77.25 | 77.99 | -252.01 | -212.92 | 5.99 | -18.41 | 0.6702 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 19.31m | 10.45% |
The Vanguard Group, Inc.as of 30 Sep 2024 | 17.50m | 9.47% |
Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 15.84m | 8.57% |
Wellington Management Co. LLPas of 30 Sep 2024 | 13.87m | 7.51% |
BlackRock Fund Advisorsas of 30 Sep 2024 | 7.42m | 4.02% |
SSgA Funds Management, Inc.as of 30 Sep 2024 | 6.68m | 3.62% |
William Blair Investment Management LLCas of 30 Sep 2024 | 4.64m | 2.51% |
Artisan Partners LPas of 30 Sep 2024 | 3.81m | 2.06% |
JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 3.48m | 1.89% |
T. Rowe Price Investment Management, Inc.as of 30 Sep 2024 | 3.39m | 1.84% |